Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified… Read More
Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia. The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US. Along with positive Phase… Read More
Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML). The data observed from the first treated patient support the… Read More
Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma. The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with… Read More
An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. The trial results have been revealed by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at… Read More
Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. In collaboration with global pharma companies, Cancer Research… Read More
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More
Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More
Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE). The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack of clinical trials… Read More
The UK government has promised that patients will benefit from cutting-edge new treatments with the introduction of a Vaccine Taskforce style approach to tackling health challenges. The government has committed over £113 ($135) million to fund research into four healthcare missions – cancer, obesity, mental health and addiction. Building… Read More
Cancer Research UK, The University of Manchester and Roche have opened a multi-drug, precision medicine trial for people with rare cancers. The trial is set up to recruit both paediatric and adult patients with any rare cancer type and is one of very few precision medicine platform… Read More
Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs. Using Nobel Prize-winning microscopy techniques, the researchers revealed how the tankyrase protein switches itself on and off… Read More
Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals. The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an… Read More
Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded. The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More
Scientists from Oxford University and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow. The technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual… Read More
New research has found variable voltages in the membranes of breast cancer cells, revealing clues about how they grow and spread. The study, led by Imperial College London and The Institute of Cancer Research, London, could help us better understand how cancer cells ‘decide’ when to multiply and where to… Read More
